German plant-based drugs and natural medicines company ABTEI-Pharma-Vertriebs GmbH has bought back the 25% stake in its capital which has been held by Procordia of Sweden, so reverting to being a family business. However, ABTEI has said that it will seek a new partner to make rapid international growth possible.
ABTEI sales rose from 61 million to 163 million Deutschemarks ($103.5 million) between 1989 and 1994. It has a 22% share of the German non-pharmacy market for its products range and is the market leader in the self-service segment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze